Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy

James L Reading; Sergio A Quezada

doi:10.1016/j.immuni.2016.12.004

Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy

Immunity. 2016 Dec 20;45(6):1181-1183. doi: 10.1016/j.immuni.2016.12.004.

Authors

James L Reading¹, Sergio A Quezada²

Affiliations

¹ Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
² Cancer Immunology Unit, UCL Cancer Institute, University College London, London WC1E 6DD, UK. Electronic address: [email protected].

PMID: 28002724
DOI: 10.1016/j.immuni.2016.12.004

Abstract

Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
B7-H1 Antigen
Humans
Immunotherapy
Neoplasms
Programmed Cell Death 1 Receptor / immunology*

Substances

Antibodies, Monoclonal
B7-H1 Antigen
Programmed Cell Death 1 Receptor

Grants and funding

20265/CRUK_/Cancer Research UK/United Kingdom